IONAMIN
LOE ApproachingNDAORALCAPSULE, EXTENDED RELEASEPriority Review
Approved
May 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IONAMIN is an oral extended-release capsule small-molecule drug approved in 1959 by UCB Pharma. The specific indication and mechanism of action are not publicly detailed in available data, but the product remains an active pharmaceutical on the market. This is a legacy NDA product with established clinical use.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); commercial teams face contraction and transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on IONAMIN as a legacy product offers limited upside; roles are focused on maintaining market share and managing decline rather than growth. Career development is constrained unless the team pivots to lifecycle extension, niche indication expansion, or strategic repositioning.
Brand ManagerProduct Manager
Worked on IONAMIN at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.